Immatics (NASDAQ:IMTX) Stock Price Down 3.7%

Immatics (NASDAQ:IMTX) traded down 3.7% during trading on Thursday . The company traded as low as $10.62 and last traded at $10.69. 543,089 shares changed hands during trading, an increase of 3% from the average session volume of 526,042 shares. The stock had previously closed at $11.10.

Immatics Trading Down 5.3 %

The stock has a market capitalization of $889.78 million, a P/E ratio of -8.54 and a beta of 0.69. The stock’s 50 day simple moving average is $11.75 and its 200 day simple moving average is $10.57.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IMTX. Vestal Point Capital LP bought a new position in shares of Immatics in the 4th quarter worth about $22,113,000. Goldman Sachs Group Inc. lifted its position in shares of Immatics by 324.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock worth $16,310,000 after buying an additional 1,183,860 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Immatics by 13.3% in the 4th quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after buying an additional 747,772 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Immatics by 44.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,334,169 shares of the company’s stock worth $24,579,000 after buying an additional 719,634 shares during the last quarter. Finally, RTW Investments LP lifted its position in shares of Immatics by 75.7% in the 4th quarter. RTW Investments LP now owns 1,484,911 shares of the company’s stock worth $15,636,000 after buying an additional 639,911 shares during the last quarter. 64.41% of the stock is currently owned by institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.